Rocket Pharmaceuticals (RCKT) Accumulated Expenses (2014 - 2026)

Rocket Pharmaceuticals has reported Accumulated Expenses for 13 years, with the latest figure at $5.2 million in Q1 2026.

• Quarterly Accumulated Expenses fell 25.99% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (down 25.99% YoY) and the FY2025 annual result came in at $12.3 million, up 2.93% from the prior year.
• Accumulated Expenses declined to $5.2 million in Q1 2026 per RCKT's latest filing, from $12.3 million in the prior quarter.
• Over five years, Accumulated Expenses peaked at $12.3 million in Q4 2025 and troughed at $405000.0 in Q2 2022.
• A 5-year average of $7.1 million and a median of $7.3 million in 2024 frame the typical range for Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Accumulated Expenses sank 73.57% in 2022, then jumped 1384.69% in 2023.
• Over 5 years, Accumulated Expenses stood at $10.0 million in 2022, then retreated by 0.76% to $9.9 million in 2023, then increased by 20.28% to $11.9 million in 2024, then grew by 2.93% to $12.3 million in 2025, then sank by 57.42% to $5.2 million in 2026.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $5.2 million, $12.3 million, and $11.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.